Katherine Angela Benson

Katherine Angela Benson

Auto-generated profile, based on publicly available information

Katherine Angela Benson

School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Ireland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Kidney International
Verified
Journal Article
Closed access
DCDervla M. Connaughton
Dervla M. Connaughton
CKClaire Kennedy
Claire Kennedy
SSShirlee Shril
Shirlee Shril
NMNina Mann
Nina Mann
SMSusan L. Murray
Susan L. Murray
FHFriedhelm and Sabine Hildebrandt
Friedhelm and Sabine Hildebrandt

3 December 2023 in Genetics in Medicine
Verified
Journal Article
Closed access
RSRyan J. Schmidt
Ryan J. Schmidt
MSMarcie Steeves
Marcie Steeves
PBPinar Bayrak-Toydemir
Pinar Bayrak-Toydemir
KBKatherine A. Benson
Katherine A. Benson
BCBradley P. Coe
Bradley P. Coe
YFYuxin Fan
Yuxin Fan

1 April 2020 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
KBKatherine A. Benson
Katherine A. Benson
MWMaire White
Maire White
NANicholas M. Allen
Nicholas M. Allen
SBSusan Byrne
Susan Byrne
RCRobert Carton
Robert Carton
GCGianpiero L. Cavalleri
Gianpiero L. Cavalleri

6 June 2022 in EBioMedicine
Verified
Journal Article
Open access
CCCiarán Campbell
Ciarán Campbell
CLCostin Leu
Costin Leu
YFYen-Chen Anne Feng
Yen-Chen Anne Feng
SWStefan Wolking
Stefan Wolking
CMClaudia Moreau
Claudia Moreau
GCGianpiero L. Cavalleri
Gianpiero L. Cavalleri
The developmental and epileptic encephalopathies (DEEs) are the most severe group of epilepsies which co-present with developmental delay and intellectual disability (ID). DEEs usually occur in people without a family history of epilepsy and have emerged as primarily monogenic, with damaging rare mutations found in 50% of patients. Little is known about the genetic architecture of patients with DEEs in whom no pathogenic variant is identified. Polygenic risk scoring (PRS) is a method that measures a person's common genetic burden for a trait or condition. Here, we used PRS to test whether genetic burden for epilepsy is relevant in individuals with DEEs, and other forms of epilepsy with ID. Genetic data on 2,759 cases with DEEs, or epilepsy with ID presumed to have a monogenic basis, and 447,760 population-matched controls were analysed. We compared PRS for ‘all epilepsy’, ‘focal epilepsy’, and ‘genetic generalised epilepsy’ (GGE) between cases and controls. We performed pairwise comparisons between cases stratified for identifiable rare deleterious genetic variants and controls. Cases of presumed monogenic severe epilepsy had an increased PRS for ‘all epilepsy’ (p<0.0001), ‘focal epilepsy’ (p<0.0001), and ‘GGE’ (p=0.0002) relative to controls, which explain between 0.08% and 3.3% of phenotypic variance. PRS was increased in cases both with and without an identified deleterious variant of major effect, and there was no significant difference in PRS between the two groups. We provide evidence that common genetic variation contributes to the aetiology of DEEs and other forms of epilepsy with ID, even when there is a known pathogenic variant of major effect. These results provide insight into the genetic underpinnings of the severe epilepsies and warrant a shift in our understanding of the aetiology of the DEEs as complex, rather than monogenic, disorders. Science foundation Ireland, Human Genome Research Institute; National Heart, Lung, and Blood Institute; German Research Foundation.

1 January 2019 in Renal Failure
Verified
Journal Article
Open access
SCS. Cormican
S. Cormican
DCD. M. Connaughton
D. M. Connaughton
CKC. Kennedy
C. Kennedy
SMS. Murray
S. Murray
MŽM. Živná
M. Živná
PCP. J. Conlon
P. J. Conlon
Introduction: Autosomal dominant tubulointerstitial kidney disease (ADTKD) is a rare genetic cause of renal impairment resulting from mutations in the MUC1, UMOD, HNF1B, REN, and SEC61A1 genes. Neither the national or global prevalence of these diseases has been determined. We aimed to establish a database of patients with ADTKD in Ireland and report the clinical and genetic characteristics of these families. Methods: We identified patients via the Irish Kidney Gene Project and referral to the national renal genetics clinic in Beaumont Hospital who met the clinical criteria for ADTKD (chronic kidney disease, bland urinary sediment, and autosomal dominant inheritance). Eligible patients were then invited to undergo genetic testing by a variety of methods including panel-based testing, whole exome sequencing and, in five families who met the criteria for diagnosis of ADTKD but were negative for causal genetic mutations, we analyzed urinary cell smears for the presence of MUC1fs protein. Results: We studied 54 individuals from 16 families. We identified mutations in the MUC1 gene in three families, UMOD in five families, HNF1beta in two families, and the presence of abnormal MUC1 protein in urine smears in three families (one of which was previously known to carry the genetic mutation). We were unable to identify a mutation in 4 families (3 of whom also tested negative for urinary MUC1fs). Conclusions: There are 4443 people with ESRD in Ireland, 24 of whom are members of the cohort described herein. We observe that ADTKD represents at least 0.54% of Irish ESRD patients.

10 December 2019 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
SMSusan L. Murray
Susan L. Murray
ADAnthony Dorman
Anthony Dorman
KBKatherine A. Benson
Katherine A. Benson
DCDervla M. Connaughton
Dervla M. Connaughton
CSCaragh P. Stapleton
Caragh P. Stapleton
PCPeter J. Conlon
Peter J. Conlon
Background: Renal biopsy is the mainstay of renal pathological diagnosis. Despite sophisticated diagnostic techniques, it is not always possible to make a precise pathological diagnosis. Our aim was to identify a genetic cause of disease in patients who had undergone renal biopsy and determine if genetic testing altered diagnosis or treatment. Methods: Patients with suspected familial kidney disease underwent a variety of next-generation sequencing (NGS) strategies. The subset of these patients who had also undergone native kidney biopsy was identified. Histological specimens were reviewed by a consultant pathologist, and genetic and pathological diagnoses were compared. Results: Seventy-five patients in 47 families underwent genetic sequencing and renal biopsy. Patients were grouped into 5 diagnostic categories based on pathological diagnosis: tubulointerstitial kidney disease (TIKD; n = 18); glomerulonephritis (GN; n = 15); focal segmental glomerulosclerosis and Alport Syndrome (n = 11); thrombotic microangiopathy (TMA; n = 17); and nonspecific pathological changes (n = 14). Thirty-nine patients (52%) in 21 families (45%) received a genetic diagnosis; 13 cases (72%) with TIKD, 4 (27%) with GN, 6 (55%) with focal segmental glomerulosclerosis/Alport syndrome, and 10 (59%) with TMA and 6 cases (43%) with nonspecific features. Genetic testing resulted in changes in understanding of disease mechanism in 21 individuals (54%) in 12 families (57%). Treatment would have been altered in at least 26% of cases (10/39). Conclusions: An accurate genetic diagnosis can result in changes in clinical diagnosis, understanding of pathological mechanism, and treatment. NGS should be considered as a complementary diagnostic technique to kidney biopsy in the evaluation of patients with kidney disease.